Drug intelligence / Profile preview

ATX5

Development stage: Preclinical
Lead developer: Aurobac Therapeutics
Modality: Small Molecules

Overview

ATX5 is a small molecule antimicrobial candidate currently in the discovery phase of development by Aurobac Therapeutics. It is being designed to target Gram-negative bacterial infections, which represent a significant area of unmet medical need due to increasing antibiotic resistance. Aurobac Therapeutics, a joint venture between Boehringer Ingelheim, Evotec, and bioMérieux, focuses on developing precision medicines and next-generation antimicrobials to combat antimicrobial resistance (AMR) and improve outcomes for patients with severe infections.

Beyond the preview

Go deeper on ATX5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX5.

Explore the full profile